anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the study, intercostal muscle oxygenation will be measured in different exercise capacity tests. A total of 32 healthy young women and men between the ages of 18-25 who meet the inclusion criteria and voluntarily agree to participate in the study will be included in the study. The cases will be randomized into 2 groups: Six minute walking test group and incremental shuttle walking test group. Heart rate, oxygen saturation, and fatigue levels will be measured with the modified Borg scale before and after the tests. During the tests, oxygen levels of the intercostal muscles will be monitored with the MOXY device. After sufficient wash out time, the groups will be crossed and different exercise tests will be applied to the cases. The result of our study will provide information about the use of intercostal muscles during different exercise tests. As a result of the study, results that can be interpreted for patient groups with circulatory system, respiratory system and physical limitations will be obtained.
Hypoxic-ischemic encephalopathy (HIE) is a severe neurological disorder caused by perinatal asphyxia with significant consequences. Early recognition and intervention are crucial, with therapeutic hypothermia (TH) being the primary treatment, but its efficacy depends on early initiation of treatment. Accurately assessing the HIE severity in neonatal care poses challenges, but omics approaches have made significant contribution to understanding its complex pathophysiology. Our study further explores the impact of HIE on the blood metabolome over time and investigated changes associated with hypothermia's therapeutic effects. Using a rat model of hypoxic-ischemic brain injury, we comprehensively analyzed dried blood spot samples for fat-soluble compounds using HPLC-MS. Our research shows significant changes in the blood metabolome after HIE, with a particularly rapid recovery of lipid metabolism observed. Significant changes in lipid metabolites were observed after 3 h of HIE, including increases in ceramides, carnitines, certain fatty acids, phosphocholines, and phosphoethanolamines, while sphingomyelins and N-acylethanolamines (NAEs) decreased (p < 0.05). Furthermore, NAEs were found to be significant features in the OPLS-DA model for HIE diagnosis, with an area under the curve of 0.812. TH showed a notable association with decreased concentrations of ceramides. Enrichment analysis further corroborated these observations, showing modulation in several key metabolic pathways, including arachidonic acid oxylipin metabolism, eicosanoid metabolism via lipooxygenases, and leukotriene C4 synthesis deficiency. Our study reveals dynamic changes in the blood metabolome after HIE and the therapeutic effects of hypothermia, which improves our understanding of the pathophysiology of HIE and could lead to the development of new rapid diagnostic approaches for neonatal HIE.
Postural-suprapostural task is defined as postural control takes place while another concurrent task is being performed, belonging to dual-task paradigms. Effective dual-task training is important to patients with Parkinson disease (PD), because they often lose balance and fall in dual-task conditions. Attentional strategy includes 1) task-priority between postural and suprapostural tasks and 2) internal and external focus for the postural task, which is the critical factor for both dual-task control and motor learning. However, the appropriateness of attentional strategy has not been investigated in dual-task training in patients with PD. Besides, there is lack of neural evidence of brain plasticity for previous studies about dual-task training in patients with PD. With the uses of EEG, EMG and behavioral measures, the purpose of this 3-year research project is to investigate the differences in performance quality and intrinsic neural mechanisms of dual-task training in PD, by adopting task-priority strategy and internal/external strategy during weight-shifting and walking. In the first year, the investigators will characterize task-priority effect (posture-priority vs. supraposture-priority) on dual-task training, with a special focus on modulation of brain plasticity and muscle activity patterns in weight-shifting posture for patients with PD. In the second and third years, the learning effects of walking internal/external focus on walking automaticity and brain plasticity will be investigated in dual-task walking training for PD patients with/without freezing of gait. Besides, the transfer effects of dual-task learning will be also investigated on medication "off" state. The present project is expected to have significant contributions not only to gain a better insight to neural correlates of dual-task training with different attentional strategies under weight-shifting and walking, but to optimize treatment strategy for PD patients with balance or dual-tasking disturbances.
PURPOSE:To concentrate efficiently the titled globulin, by defatting cow's colostrum, adding an acid to the defatted cow's colostrum to adjust the pH to a specific value, adding pepsin or rennin thereto to coagulate and separate casein, and ultrafiltering the resultant whey. CONSTITUTION:A colostrum collected within about one week after the delivery of a cow is defatted with a cream separator, and an acid, e.g. acetic or propionic acid, is added to the defatted colostrum to adjust the pH to 5.0-6.0. Pepsin or rennin is then added thereto coagulate casein. In the process, the defatted colostrum is preferably heated to 50-55 deg.C. Crud is flocculated by heating, and whey is collected. The recovered whey is then contrifuged at a low speed, and the remaining fine particles are removed. The whey is then preferably quenched to 10 deg.C or below. The resultant whey is concentrated in an ultrafiltration apparatus, e.g. plate form, etc. The resultant whey containing concentrated immunoglobulin is freeze-dried or spray-dried to give a raw material used to prepare a feed for young animals.
The side effects of Pyridostigmine Bromide Tablets are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis and diaphoresis. Nicotinic side effects are comprised chiefly of muscle cramps, fasciculation and weakness. Muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. As with any compound containing the bromide radical, a skin rash may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication.

To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Control participants will receive usual care during their year of enrollment. At enrollment, prior to randomization, they will be informed that, if randomized to control status, they will be offered a free BP monitor and the opportunity to receive the study intervention after completing the exit interview in 1 year.
This randomized clinical trial will be conducted to compare the drug sertraline to cognitive behavioral therapy on symptoms of depression, antiepileptic medication compliance, seizure frequency, and quality of life outcomes in persons with depression and a seizure disorder or epilepsy. Approximately 140 persons will be enrolled in this study over a period of five years. Individual participation will last approximately 16 weeks. Study participants will be chosen randomly to receive either the study medication (sertraline) or cognitive behavior therapy for 16 weeks. Sertraline is approved by the Food and Drug Administration (FDA). Subjects who receive cognitive behavior therapy will be provided with a one-hour individual session with a licensed clinical psychologist each week for 15 weeks. All study participants will attend scheduled clinic visits every 4 weeks for 16 weeks.
BACKGROUND: The formation of macrosomia is associated with excessive nutrition and/or unable to regulate effectively. This case-control study aims to explore the relationship between macrosomia and glucose, lipids and hormones levels in maternal and cord serum.
METHODS: In the case-control study, 78 pairs of mothers and newborns were recruited who received care at one hospital of Hebei, China between 2016 and 2019. According to the birth weight (BW) of newborns, participants were divided into macrosomia group (BW ≥ 4000 g, n = 39) and control group (BW between 2500 g and 3999 g, n = 39). Maternal vein blood and cord vein blood were collected and assayed. All data were compared between the two groups. Unconditional logistics regression analysis was used to test the relationship between macrosomia and glucose, lipids and hormones in maternal and cord serum.
RESULTS: In maternal and cord serum, the levels of leptin, leptin/adiponectin ratio (LAR), glucose and triglyceride (TG) in macrosomia group were higher than those in control group, and the levels of high-density lipoprotein cholesterol (HDL-C) were lower. The percentage of maternal glucose and lipids transfer to cord blood did not differ between the two groups. High levels of TG in maternal serum were positively correlated with macrosomia, and high levels of LAR, TG and glucose in cord serum were positively correlated with macrosomia.
CONCLUSION: In conclusion, the results of the current study, suggest that the nutrients and metabolism-related hormones in maternal and umbilical cord are closely related to macrosomia. During pregnancy, the nutritional status of pregnant women should be paid attention to and to obtain a good birth outcome.
The invention provides an allogeneic universal CAR-T cell targeting SIGLEC-6 and a preparation method and application thereof, and relates to the technical field of biological medicine. The invention takes human SIGLEC-6 as a target point to prepare an anti-SIGLEC-6 nanobody, wherein the nanobody comprises a heavy chain variable region comprising CDR1, CDR2 and CDR 3: the CDR1 is shown as SEQ ID NO.1, the CDR2 is shown as SEQ ID NO.2, and the CDR3 is shown as SEQ ID NO. 3; or the CDR1 is shown as SEQ ID NO.5, the CDR2 is shown as SEQ ID NO.6, and the CDR3 is shown as SEQ ID NO. 7. The nano antibody can be specifically combined with SIGLEC-6 antigen, has the affinity of 10  ‑10 ～10 ‑11  M, and belongs to high-affinity nano antibodies. The allo-general CAR-T cells prepared from the nano antibody have good anti-tumor activity, can be applied to preparation of medicines for preventing, diagnosing and treating SIGLEC-6 positive leukemia and lymphoma, in particular AML, CLL, MALT lymphoma, clonal mast cell diseases and the like, and have good application prospects.
BACKGROUND: Few studies have explored the correlation between overactive bladder (OAB) and suicidal ideation. This study aims to investigate the association between OAB and suicidal ideation, as well as the relationship between OAB and all-cause mortality among individuals with suicidal ideation.
METHODS: Data from the 2005-2018 National Health and Nutrition Examination Survey (NHANES) were analyzed using cross-sectional and cohort study designs. Weighted multivariable logistic regression models were used to examine the association between OAB and suicidal ideation. Kaplan-Meier curves and weighted multivariable Cox proportional hazards models assessed the relationship between OAB and all-cause mortality among those with suicidal ideation. Interaction analyses on subgroups were conducted to validate the findings. Mediation analysis was performed to examine the effect of depression on the relationship between OAB and suicidal ideation.
RESULTS: Among 33,426 participants aged ≥ 20 years, 1,290 (3.8%) reported suicidal ideation. After adjusting for potential confounders, participants with OAB were 2.57 times more likely to have suicidal ideation (P < 0.001). Over an average follow-up of 87 months, 197 participants with suicidal ideation died. The Cox model revealed that participants with OAB had a 3.08 times higher risk of death (P = 0.006). Kaplan-Meier curves indicated higher survival rates for non-OAB participants. Mediation analysis indicates that depression significantly mediates the relationship between OAB and suicidal ideation, with a mediation proportion of 75.25% (P < 0.001).
CONCLUSIONS: OAB is positively associated with the incidence of suicidal ideation and all-cause mortality among participants with suicidal ideation. Additionally, the association between OAB and suicidal ideation is mediated by depression.
Fractions contg. oligomeric procyanidines with cardiac and circulatory activity are isolated from the berries of Crataegus spp. by (a) extracting the fresh berries with an org. water-miscible solvent contg. 0-50% H2O at 10-80 degrees C; (b) extracting the extract at 15-50 degrees C with a lipophilic water-immiscible solvent; (c) treating the H2O-contg. org. phase with (NH4)2SO4 to 20-30% satn. and extracting with an org. solvent of b.pt. 60-110 degrees C having a known solubility in H2O; (d) drying the extract in known manner, evaporating and exhaustively extracting the residue with a lower aliphatic alcohol; and (e) evaporating the extract and either drying the residue or neutralising it in aq. soln. with MgO or a basic Na cpd. and then evaporating.
Store unopened vials in refrigerator, 2° to 8°C (36° to 46°F). Store prepared solution for infusion at room temperature, 15° to 30°C (59° to 86°F) for up to 24 hours. Contains no preservative. Discard unused portion. Protect from light.

If daunorubicin hydrochloride contacts the skin or mucosae, the area should be washed thoroughly with soap and water. Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1-7 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
Embodiments of the invention provide techniques for using digital imaging and networked communications in clinical hematology. An Area of Interest (AOI) on a slide is determined. A high resolution image of the AOI  is analyzed for sample integrity and adjusted and rescanned based on programmable parameters. Sensitive HIPAA  information is removed from the AOI image stored on a server.  The server includes Web 2.0 software applications. A remote user reviews the image and adds metadata to the server.  The server manages the work flow between the stored AOI  images and the available users. A technician accesses information about a particular image file, as well as other topics, through knowledge management and social network applications.    Lab reports are generated based on the metadata. The quality of the metadata is subject to quality control processes.  The stored images and associated metadata can be mined for subsequent medical research.
PROBLEM TO BE SOLVED: To obtain an administration form of a semi-transparent, suitably viscous gelating medicine capable of being recognized by the eye, such as a gelatin capsule, comprising a sealing material and plural phases, which are disposed in regions apart from the sealing material and which are brought into contact with each other at at least one interface. SOLUTION: This administration form comprises a general sealing material comprising a polymer material, the first phase containing the first semi-solid filling material, and the second phase containing the second semi-solid filling material. At least one of the first and second phases contains an active ingredient (e.g. a medicine such as acetaminophen). The first and second phases are disposed in the regions apart from the sealing material, respectively, brought into contact with each other at at least one surface, and have different compositions, respectively. At least one of the phases has a turbidity of <=1300NTU.
PURPOSE:To provide an inexpensive antifatigue food agreeable to take and having high antifatigue effect, by using the powder and/or extract of onion and adzuki bean and oyster meat extract as essential components. CONSTITUTION:The objective food contains (A) the powder and/or extract of onion (Allium cepa) and adzuki bean (Vigna angularis Ohwi lt Ohashi) and (B) extract of oyster meat (Ostrea gigas Thunb), as essential components. The oil of onion, i.e. propyl allyl disulfide (C3H707) and allyl sulfide [(C3H5)S] is effective to promote the activation of vitamin B1, metabolize the glucoside safely, and prevent the accumulation of fatigue-inducing substance. The glucogen in the oyster meat extract promotes the detoxication effect. The hydrogogic effect of adzuki bean is effective to promote the excretion of the fatigue- inducing substance and the detoxication product and exhibit the effective anti- fatigue effect.
This phase I/II non randomized single center study will be performed as a two step design. Part I is dose finding, whereby dose escalations will be performed for everolimus and capecitabine. Part II is the efficacy study. At the MTD doses in part II biomarker studies will be performed in blood and tumor tissue. Study design phase I part: The first week patients will be treated with everolimus alone. Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8. Cetuximab will be administered weekly, starting at day 8. The dose is fixed for cetuximab during study treatment, whereas the doses of everolimus and capecitabine will differ per dose level. First dose level: Everolimus 5 mg daily continuously, Capecitabine 600 mg/m2 bid for 2 weeks every 3 weeks, Cetuximab 400mg/m2 (120 min infusion) first dose, thereafter 250 mg/m2 (60 min infusion) weekly. Second dose level: Everolimus 10 mg daily continuously, Capecitabine 600 mg/m2 bid for 2 weeks every 3 weeks, Cetuximab 400mg/m2 (120 min infusion) first dose, thereafter 250 mg/m2 (60 min infusion) weekly. Third dose level: Everolimus 10 mg daily continuously, Capecitabine 800 mg/m2 bid for 2 weeks every 3 weeks, Cetuximab 400mg/m2 (120 min infusion) first dose, thereafter 250 mg/m2 (60 min infusion) weekly. Study design phase II part At the MTD 14-25 patients with pancreatic cancer will be included. In the phase II part, everolimus will be administered during one week before start of cetuximab. At day 8 the first dose of cetuximab will be administered. Capecitabine will be started one week thereafter. This enables us to perform pharmacodynamic studies to assess biomarker changes during the different phases of treatment. Everolimus will be administered continuously in a dose of 5 or 10 mg orally once daily (dependent on MTD from part 1). Capecitabine will be administered orally in a dose of 400 - 800 mg/m2 twice daily for 14 days followed by one week rest (dependent on MTD from part 1). Patients will receive cetuximab infusions via an infusion pump, with an initial dose of 400 mg/m² (over 120 min) and subsequent weekly infusions of 250 mg/m² (over 60 min), starting day 8.
Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who progress also receive oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of a second disease progression or unacceptable toxicity.
The present invention relates to a medicine for treating liver diseases, which is prepared from Chinese caterpillar fungus, centipede, cadaver aspongopi, leech, long-noded pit viper, cantharis, ground beeltle, earth worm and silkworm larva by soak, pulverization, mixing and sterilization. The medicine treats malignant pathogens by poisonous agents without side effect. The present invention has the advantages of easy absorption, rapid effect taking and high therapeutic effect. The present invention is a good updating medicine for treating liver diseases. The present invention is broadly suitable for the treatment of various liver diseases (such as hepatomegaly, liver ascites, liver cancer, etc.), diabetes, cardiovascular and cerebrovascular diseases and winddampness.
PROBLEM TO BE SOLVED: To detect and verify the existence or absence of interaction between pharmaceuticals in a good productivity. SOLUTION: A written information about interaction between pharmaceuticals consists of a heading part consisting of the names of pharmaceuticals and a text carrying information about the interaction involving the pharmaceutical named in the heading, as information for every pharmaceutical. In the text, a different paragraphing indicates a different degree of importance of interaction. Using a name for retrieval and names equivalent to the name for retrieval, necessary information is retrieved from the interaction-related information that the text carries.  Upon success in retrieving necessary information from the text, the pharmaceutical named in the heading to this text is judged as the other party possibly to cause interaction with the pharmaceutical used to start the retrieval with, and the paragraphing of the part carrying the retrieved information is represented by a interaction importance rank. A record of a combination of the pharmaceutical name used for retrieval, the name of the pharmaceutical that is the other party of interaction, and the interaction gravity rank, is treated as an article of interaction verification data.
PURPOSE: Smoking is a risk factor for sarcopenia. Nevertheless, few studies analyzed the independent effects of various smoking dimensions (duration, intensity, cumulative dose) on sarcopenia risk. This is a cross-sectional study based on an older population in Zhejiang Province to determine which smoking dimensions are mainly important for sarcopenia risk and to explore the dose-response relationship between them.
METHODS: Our study included 783 patients with sarcopenia and 4918 non-sarcopenic individuals. Logistic regression and restricted cubic with logistic regression (for nonlinear dose effects) were used to obtain odds ratios (ORs) and 95% confidence intervals as well as restricted cubic splines (RCS) curves.
RESULTS: Compared with never-smokers, current smokers had an increased risk of sarcopenia (OR = 1.786; 95% CI 1.387-2.301) after adjusting for confounders such as age, sex, education, alcohol consumption, disease history, etc. There was no significant association between smoking intensity and sarcopenia after more than 20 cigarettes per day (OR = 1.484; 95% CI 0.886-2.487), whereas the risk of sarcopenia increased significantly with increasing duration of smoking after more than 40 years (OR = 1.733; 95% CI 1.214-2.473). Meanwhile, there was a significant non-linear dose-response relationship between smoking duration or intensity and the risk of sarcopenia. However, the risk of sarcopenia increased linearly with the number of pack-years of smoking, which is not a significant nonlinear dose-response relationship.
CONCLUSIONS: This study indicated the association between smoking and sarcopenia. Both smoking duration and cumulative dose were significantly and positively associated with sarcopenia. These findings reflect the important role of the number of years of smoking in increasing the risk of sarcopenia and provide scientific evidence that different smoking dimensions may influence the risk of the sarcopenia.